ERBB2 and breast cancer: For instance, in ongoing or recently completed clinical trials the efficacy of the intravenous infusions of TCR-modified T cells against antigens such as HER2, NY ESO-1, and MAGE-A3 alone or in combination with anti-PD-1 therapy in BC patients has been evaluated, nevertheless, with no reported interim results yet (NCT03159585, NCT02111850).